Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 18, 2011

BioNanomatrix Closes $23.3M Financing to Set Up West Coast Presence

  • BioNanomatrix has closed a $23.3 million Series B round of equity financing. The company will use the money to establish a presence on the West Coast for its business, focused on nanoscale, single-molecule imaging and analysis platforms.

    “The Series B financing comes at a pivotal time for the company, as we advance toward commercialization of our unique nanoAnalyzer platform for whole genome analysis,” says R. Erik Holmlin, president and CEO of BioNanomatrix.

    Holmlin says that BioNanomatrix has already placed its nanoAnalyzer 1000 systems with early-access users since introducing the system last November at the 2010 annual meeting of the American Society of Human Genetics.

    BioNanomatrix is based in Philadelphia, and the new West Coast presence “will provide additional business opportunities and the ability to recruit from a talent base that has established this industry,” notes Brian K. Halak, Ph.D., a newly named member of the company’s board of directors.

    Dr. Halak is a partner with Domain Associates, which led the equity financing round. Domain was joined by new investor Gund Investment and existing investors Battelle Ventures, Innovation Valley Partners, and KT Venture Group.

     

     

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »